Why William Hill plc (LON:WMH) Could Be Worth Watching

    William Hill plc (LON:WMH), which is in the hospitality business, and is based in United Kingdom, led the LSE gainers with a relatively large price hike in the past couple of weeks. As a stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. But what if there is still an opportunity to buy? Today I will analyse the most recent data on William Hill’s outlook and valuation to see if the opportunity still exists.

    See our latest analysis for William Hill

    Advertisement

    What is William Hill worth?

    Great news for investors – William Hill is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is £1.63, but it is currently trading at UK£1.00 on the share market, meaning that there is still an opportunity to buy now. What’s more interesting is that, William Hill’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

    What does the future of William Hill look like?

    LSE:WMH Past and Future Earnings April 21st 2020
    LSE:WMH Past and Future Earnings April 21st 2020

    Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. In the upcoming year, William Hill’s earnings are expected to increase by 61%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

    What this means for you:

    Are you a shareholder? Since WMH is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.

    Are you a potential investor? If you’ve been keeping an eye on WMH for a while, now might be the time to make a leap. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy WMH. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy.

    Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on William Hill. You can find everything you need to know about William Hill in the latest infographic research report. If you are no longer interested in William Hill, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

    If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

    We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

    Advertisement

    Weekly Picks

    LO
    Lou_Basenese
    OPTH logo
    Lou_Basenese on Optimi Health ·

    The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

    Fair Value:US$1157.5% undervalued
    47 users have followed this narrative
    2 users have commented on this narrative
    7 users have liked this narrative
    WE
    WealthAP
    NOVO B logo
    WealthAP on Novo Nordisk ·

    Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

    Fair Value:DKK 407.7721.4% undervalued
    67 users have followed this narrative
    0 users have commented on this narrative
    8 users have liked this narrative
    VA
    ValueInvestingSubstack
    ZTS logo
    ValueInvestingSubstack on Zoetis ·

    Zoetis down -50% over the past year

    Fair Value:US$92.9218.9% undervalued
    23 users have followed this narrative
    0 users have commented on this narrative
    9 users have liked this narrative
    CE
    CentryResearch
    LEU logo
    CentryResearch on Centrus Energy ·

    Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

    Fair Value:US$19013.7% undervalued
    24 users have followed this narrative
    0 users have commented on this narrative
    10 users have liked this narrative

    Updated Narratives

    WI
    WisetoWealth
    PYPL logo
    WisetoWealth on PayPal Holdings ·

    The Underrated Transformation of a Digital Payments Giant

    Fair Value:US$90.3137.8% undervalued
    2 users have followed this narrative
    0 users have commented on this narrative
    0 users have liked this narrative
    BL
    Blagget
    TERA logo
    Blagget on Terra Balcanica Resources ·

    The C$4M Explorer Positioned to Become Europe's First Antimony Mine

    Fair Value:CA$0.487.5% undervalued
    2 users have followed this narrative
    0 users have commented on this narrative
    0 users have liked this narrative
    DA
    CHTR logo
    david_6nroa on Charter Communications ·

    Charter is undervalued - Here's why.

    Fair Value:US$87.0741.6% overvalued
    1 users have followed this narrative
    0 users have commented on this narrative
    0 users have liked this narrative

    Popular Narratives

    CU
    MSFT logo
    CubanEros on Microsoft ·

    A wonderful business at reasonable price.

    Fair Value:US$419.919.1% undervalued
    81 users have followed this narrative
    0 users have commented on this narrative
    6 users have liked this narrative
    OS
    oscargarcia
    NVDA logo
    oscargarcia on NVIDIA ·

    The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

    Fair Value:US$28026.1% undervalued
    185 users have followed this narrative
    9 users have commented on this narrative
    15 users have liked this narrative
    BE
    PYPL logo
    benjamin_lvieq on PayPal Holdings ·

    PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

    Fair Value:US$6513.6% undervalued
    71 users have followed this narrative
    2 users have commented on this narrative
    11 users have liked this narrative

    Trending Discussion

    DE
    TDOC logo
    derek_3wsdg on Teladoc Health ·

    You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

    1
    |
    0